# Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.

> **NCT03944304** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 40 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03944304
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-27
- **Primary completion:** 2025-01-06
- **Final completion:** 2025-10-14
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03944304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03944304, "Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03944304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*